Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities:
Net loss	$ (7,240,686)	$ (8,982,952)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	3,118,402	4,214,830
Amortization of debt issuance costs	367,285	276,258
Stock based compensation expense related to issuance of restricted stock	10,977	8,070
Equity in loss of unconsolidated joint venture	222,528
Unrealized derivative gain	158,595	87,000
Derivative fair value adjustment	410,657	(951,943)
Unrealized foreign currency adjustment	195,936	2,206,103
Changes in operating assets and liabilities:
Other assets, net	(316,417)	(66,166)
Purchase of interest rate derivative		(711,000)
Settlement of interest rate derivative	(2,030,731)
Accounts payable and accrued liabilities	831,030	(213,380)
Due to affiliates	2,978,762	3,347,491
Net cash used in operating activities	(1,293,662)	(785,689)
Cash flows from investing activities:
Additions to real estate facilities	(3,024,103)	(2,253,847)
Investments in unconsolidated real estate ventures	(986,166)	(6,449,918)
Net cash used in investing activities	(4,010,269)	(8,703,765)
Cash flows from financing activities:
Proceeds from issuance of secured debt	170,533,452
Repayment of secured debt	(164,535,746)
Scheduled principal payments of secured debt	(655,276)	(385,375)
Debt issuance costs	(1,765,499)
Gross proceeds from issuance of common stock	7,245,023	10,586,181
Offering costs	(805,069)	(1,035,663)
Proceeds from issuance of Series C Units	294,276	359,926
Redemption of common stock	(442,933)	(118,560)
Distributions paid to common stockholders	(2,047,641)	(1,801,202)
Distributions paid to noncontrolling interest in our Operating Partnership	(83,930)	(84,870)
Distributions paid to preferred stockholders	(3,148,361)	(3,131,250)
Net cash provided by financing activities	4,588,296	4,389,187
Impact of foreign exchange rate changes on cash and restricted cash	6,710	(483,052)
Net change in cash, cash equivalents and restricted cash	(708,925)	(5,583,319)
Cash, cash equivalents and restricted cash, beginning of period	17,565,564	25,708,071
Cash, cash equivalents and restricted cash, end of period	16,856,639	20,124,752
Supplemental disclosures and non-cash transactions:
Cash paid for interest, net of amounts capitalized	3,336,189	4,220,435
Offering costs included in accounts payable and accrued liabilities	62,904	222,836
Interest rate swap contract in other assets	790,781	663,978
Interest rate swap contracts in accounts payable and accrued liabilities	592,916	147,121
Foreign currency hedge contract in other assets	155,256
Foreign currency translation adjustment	63,949	1,550,882
Deposits applied to investments in unconsolidated real estate ventures		333,765
Issuance of shares pursuant to distribution reinvestment plan	1,600,498	1,303,340
Distributions payable to common and preferred stockholders	4,360,414	4,265,856
Distributions payable to noncontrolling interests in our Operating Partnership	28,964	28,885
Real estate and construction in process in accounts payable and accrued liabilities	714,142	384,198
Redemption of common stock in accounts payable and accrued liabilities	$ 174,377	784,542
Purchase of interest rate derivative in accounts payable and accrued liabilities		$ 415,000